Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009067013 | Prostate | Tumor | RNA localization to Cajal body | 11/3246 | 19/18723 | 8.03e-05 | 8.19e-04 | 11 |
GO:009067113 | Prostate | Tumor | telomerase RNA localization to Cajal body | 11/3246 | 19/18723 | 8.03e-05 | 8.19e-04 | 11 |
GO:009067213 | Prostate | Tumor | telomerase RNA localization | 11/3246 | 19/18723 | 8.03e-05 | 8.19e-04 | 11 |
GO:009068513 | Prostate | Tumor | RNA localization to nucleus | 11/3246 | 19/18723 | 8.03e-05 | 8.19e-04 | 11 |
GO:007020314 | Prostate | Tumor | regulation of establishment of protein localization to telomere | 8/3246 | 11/18723 | 8.11e-05 | 8.19e-04 | 8 |
GO:190486914 | Prostate | Tumor | regulation of protein localization to Cajal body | 8/3246 | 11/18723 | 8.11e-05 | 8.19e-04 | 8 |
GO:190487114 | Prostate | Tumor | positive regulation of protein localization to Cajal body | 8/3246 | 11/18723 | 8.11e-05 | 8.19e-04 | 8 |
GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
GO:190357818 | Prostate | Tumor | regulation of ATP metabolic process | 30/3246 | 87/18723 | 8.61e-05 | 8.53e-04 | 30 |
GO:004211015 | Prostate | Tumor | T cell activation | 117/3246 | 487/18723 | 9.22e-05 | 9.05e-04 | 117 |
GO:004308713 | Prostate | Tumor | regulation of GTPase activity | 88/3246 | 348/18723 | 1.04e-04 | 1.00e-03 | 88 |
GO:190481413 | Prostate | Tumor | regulation of protein localization to chromosome, telomeric region | 9/3246 | 14/18723 | 1.21e-04 | 1.14e-03 | 9 |
GO:199017314 | Prostate | Tumor | protein localization to nucleoplasm | 9/3246 | 14/18723 | 1.21e-04 | 1.14e-03 | 9 |
GO:003097012 | Prostate | Tumor | retrograde protein transport, ER to cytosol | 14/3246 | 29/18723 | 1.22e-04 | 1.14e-03 | 14 |
GO:007019813 | Prostate | Tumor | protein localization to chromosome, telomeric region | 14/3246 | 29/18723 | 1.22e-04 | 1.14e-03 | 14 |
GO:190351312 | Prostate | Tumor | endoplasmic reticulum to cytosol transport | 14/3246 | 29/18723 | 1.22e-04 | 1.14e-03 | 14 |
GO:003298413 | Prostate | Tumor | protein-containing complex disassembly | 61/3246 | 224/18723 | 1.36e-04 | 1.26e-03 | 61 |
GO:009026314 | Prostate | Tumor | positive regulation of canonical Wnt signaling pathway | 34/3246 | 106/18723 | 1.55e-04 | 1.40e-03 | 34 |
GO:005197214 | Prostate | Tumor | regulation of telomerase activity | 19/3246 | 47/18723 | 1.60e-04 | 1.44e-03 | 19 |
GO:007189714 | Prostate | Tumor | DNA biosynthetic process | 51/3246 | 180/18723 | 1.63e-04 | 1.46e-03 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CP | SNV | Missense_Mutation | novel | c.1843N>A | p.Gln615Lys | p.Q615K | P00450 | protein_coding | tolerated(0.28) | possibly_damaging(0.521) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CP | SNV | Missense_Mutation | | c.204G>T | p.Lys68Asn | p.K68N | P00450 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CP | SNV | Missense_Mutation | | c.2285A>C | p.Asn762Thr | p.N762T | P00450 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.1468N>C | p.Tyr490His | p.Y490H | P00450 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CP | SNV | Missense_Mutation | | c.616G>A | p.Asp206Asn | p.D206N | P00450 | protein_coding | tolerated(0.38) | benign(0.052) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.2254N>A | p.Glu752Lys | p.E752K | P00450 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CP | insertion | Nonsense_Mutation | novel | c.208_209insACTCATCGGACCTTTAATAATCTGTAAAAAAGGTACAT | p.Ala70AspfsTer6 | p.A70Dfs*6 | P00450 | protein_coding | | | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CP | SNV | Missense_Mutation | novel | c.224A>G | p.Tyr75Cys | p.Y75C | P00450 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CP | SNV | Missense_Mutation | | c.550N>A | p.Asp184Asn | p.D184N | P00450 | protein_coding | tolerated(0.09) | possibly_damaging(0.803) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.572N>T | p.Ser191Leu | p.S191L | P00450 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |